The New York Times (2/10, Kolata) reports researchers found that Eli Lilly’s solanezumab and Roche’s gantenerumab “did nothing to slow or stop cognitive decline in” healthy people with genetic mutations that cause dementia. The study participants all had genetic “mutations that cause an overproduction of amyloid, which accumulates in hard plaques in the brain,” and “the experimental drugs attacked amyloid” with the aim of preventing cognitive decline, but they did not appear to be effective.The AP (2/10, Marchione) reports the trial tested the two drugs in people with one of three genes that make the risk of Alzheimer’s disease extremely high. In the trial, patients with these mutations “were given either a gantenerumab shot, an IV of solanezumab or fake versions of these treatments every four weeks,” but “the drugs made no difference in a combination score of four memory and thinking tests compared to placebo treatments.” The Wall Street Journal (2/10, Loftus, Subscription Publication) and HealthDay (2/10, Preidt) also cover the story. (SOURCE: APA Headlines)
- ) strategy and implementation of activities aimed at increased supports for caregivers of persons with mental illness, in addition to the continued work of the Coalition and sustaining the collaboration between aging and behavioral health providers at the local level.
- Studies Support Effectiveness Of Ketamine, Esketamine For Difficult-To-Treat Depression, MDD With Suicidal Ideation, Expert Says
- In Small Study, Investigational Nondopamine Antipsychotic Show Signals It May Improve Psychosis Symptoms In Patients With Parkinson’s Disease
- Benzoate Treatment Appears To Improve Cognitive Function Among Women With Later-Stage Dementia In Small Study
- More Than One In Ten Patients Who Receive An ICD May Also Develop Anxiety Or Depression, Research Suggests